The success of allogeneic stem cell transplantation (SCT) is dependent not only on the intensive conditioning therapy, but also on the graft-versus-leukemia (GVL) properties of the donor graft. Unfortunately, despite recent advances, disease relapse remains a major obstacle to successful transplant in patients with acute myeloid leukemia (AML). Patients transplanted in first remission have a 10-20% relapse rate and those with more advanced disease have relapse rates of 40-60%. The treatment options for relapse have generally been limited. Second SCT may cure a minority of these patients but at the expense of extensive morbidity and mortality. A safer and more effective approach to relapse is needed. One such approach is the use of donor leukocyte infusions (DLI) to induce a direct GVL reaction for patients with relapsed AML without the need for additional myeloablative conditioning therapy.
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Kolb et al 1 first published the effective use of DLI in three patients with relapsed chronic myelogenous leukemia (CML) who all had a complete cytogenetic remission. Subsequent studies have confirmed that DLI is dramatically effective for patients with CML. In all, 70-80% of chronic phase CML patients treated with DLI achieve a complete cytogenetic response, 2, 3 and the majority of these patients achieve a molecular remission as well. DLI has been much less effective for patients with acute leukemia. Retrospective data, compiled from two large registries (the North American registry and the European Group for Blood and Marrow Transplantation) indicate that response rates to DLI for relapsed AML range from 15 to 30%. 2, 3 Response rates in acute lymphoblastic leukemia (ALL) are even lower, at about 10%.
While DLI-induced remissions are achieved in only a small number of AML patients, many of these remissions may be durable. Of 10 patients in the North American registry who had achieved a complete remission (CR) from DLI, only two subsequently relapsed at 1-3 years. At a median follow-up of 1 year, five patients were alive and in CR. The two that relapsed died of disease and three other patients had died of treatmentrelated causes. 4 The effects of DLI appear to be similar in patients receiving unrelated donor transplants, although only small numbers of recipients of unrelated DLI (UDLI) have been reported. In collaboration with the National Marrow Donor Program, we retrospectively identified 23 AML patients who received UDLI for relapsed AML. 5 The median follow-up was 10 weeks (range 4-102 weeks). Of the patients evaluable for response to DLI alone, 42% achieved a CR. However, only 4/23 of all patients (17%) had a durable CR. From this study and others, it is clear that the most significant predictor of survival and disease-free survival (DFS) was the time from transplant to relapse. 6 Of interest, there was no dose-response effect identified in the unrelated donor setting though the majority of patients received more than 1 Â 10 7 mononuclear cells/kg. Although a minority of patients will achieve a durable CR after DLI, one factor limiting the response has been the high tumor burden and rapid proliferation of leukemic blasts. Since the effects of DLI may be delayed, there is significant disease-related early mortality after DLI, but before the antileukemia effect is manifest. It is therefore logical to administer chemotherapy before DLI to limit the leukemia burden. A recent prospective trial used induction chemotherapy followed by GCSF-primed DLI in 65 patients with relapsed AML. 7 Patients received 1 Â 10 8 /kg CD3-positive cells, the median time from transplant to relapse was 100 days, and the median time from relapse to DLI was 19 days. Of 65 patients, 27 (42%) achieved a CR, but only nine (14%) were in continuous CR at a median of 29 months after DLI. Eight patients were not evaluable because of early death and 25 of 30 evaluable patients who did not respond died from progressive disease. It was notable, however, that 10 patients who did not respond received additional DLI and three achieved a CR. One of the most important predictors of overall survival was time from transplant to relapse. In patients who relapsed more than 6 months after transplant, the overall survival was almost 40% at 2 years compared to almost no patients surviving if they had relapsed within 6 months of transplant. These results are comparable to historical controls using DLI where the response rates vary anywhere from 0 to 30% and DFS is 3-20%.
Unfortunately, not only response to DLI in AML is disappointing, but also the toxicity is significant. Up to 30% of patients will develop grade III-IV acute GVHD, and treatment-related mortality rates are estimated to be up to 20%. Although not specific for AML, several novel strategies have been used to both minimize toxicity from GVHD and to enhance the GVL effects of DLI. Since T-cell depletion results in increased relapsed rates, one strategy under study at several centers has been the use of a T-cell-depleted marrow graft followed by delayed add-back of donor T cells to restore lost GVL activity. 8, 9 This approach appears to be effective for patients with CML 10 and may also have a role for patients with acute leukemia. 11 In one trial that included 82 patients with a variety of diseases, pre-emptive DLI resulted in improved 3-year DFS though was complicated by unacceptable GVHD when given at 0.7 Â 10 8 CD3 cells/kg; only eight of 25 patients who received 0.1 m Â 10 8 CD3 cells/kg developed grade I-II acute GVHD. 11 In CML, other successful approaches to minimize GVHD have included the use of low-dose DLI with gradual dose escalation, 12 depletion of CD8-positive cells from the donor product, 13, 14 and the use of irradiated (and hence inactivated) DLI. 15 These strategies appear useful for patients with CML, but have not been studied in detail for patients with AML. In a more direct effort to regulate GVHD, a herpes simplex virus thymidine kinase suicide gene, which confers sensitivity to ganciclovir, has been transduced into donor T cells used for DLI. These cells have been effective to treat post-transplant lymphoproliferative disorder and subsequent GVHD was successfully treated with ganciclovir. 16 Several other strategies are being investigated not just to minimize GVHD but also to enhance GVL activity of DLI for a variety of malignancies, including AML. In some cases, it may be possible to generate leukemia-specific, or lineage-restricted, cytotoxic T cells. Directed cell therapy holds the potential to induce GVL without a nonspecific GVHD reaction. Although target antigens for GVL activity are largely unknown, several possibilities can be considered. Several tumors express novel epitopes, such as bcr/abl in CML, that are potential, though theoretical, targets for DLI. 17 Alternative targets being tested are overexpressed normal antigens, such as proteinase-3 in CML patients 18 as well as lineage-restricted minor histocompatibility antigens. [19] [20] [21] It may also be possible to activate donor T cells in a nonspecific manner to enhance GVL activity. For instance, in vivo activation with interleukin-2 given after DLI has resulted in remissions in some patients with CML and ALL, although patients with AML did not respond. 22 At the University of Pennsylvania, we are exploring the role ex vivo activated DLI in an effort to enhance the antileukemic activity of donor T cells. Although DLI is disease specific, the actual mechanisms for disease specificity are not known. One hypothesis for the lack of GVL activity in AML is that donor T cells are not appropriately activated in vivo to induce a GVL reaction. Ex vivo activation by costimulation and expansion may reverse functional T-cell tolerance and/or augment GVL activity. For instance, ex vivo costimulation of autologous T cells by CD3 and CD28 can reverse functional defects in patients with lymphoma both in vivo and in vitro. 23 It is therefore possible that ex vivo costimulated and expanded donor T cells will induce GVL in patients who do not otherwise respond well to DLI. Costimulation and ex vivo activation is performed through exposure of donor T cells to superparamagnetic beads linked with anti-CD28 and anti-CD3 antibodies that will appropriately engage donor T cells, 24 and results in four-to 16-fold T-cell expansion for use as DLI. The magnetic nature of the beads allows removal after activation.
Our current phase I trial is designed for patients with diseases that do not respond well to traditional DLI therapy. For patients with acute leukemia, standard induction chemotherapy is used to limit the leukemia burden. Unstimulated donor T cells are then given as 'standard DLI' 10-14 days after induction. An aliquot of these T cells is taken for ex vivo costimulation and expansion and reinfused approximately 12 days after standard DLI. To date, seven patients with hematologic malignancies have been treated (three ALL, three AML, and one chronic lymphocytic leukemia). 24 Three patients (one each with AML, ALL and CLL) achieved a CR with remission durations of 22 to over 65 weeks. One patient treated for AML has been in remission for more than 15 months, follow-up is insufficient in one AML patient and the third was not evaluable for response because of early death. Two patients with ALL died of progressive disease and one achieved a CR. Grade I-II acute GVHD (skin only) developed in the three responding patients and was successfully treated with standard immunosuppressive therapy.
Based on the experience using DLI to treat relapsed disease after allogeneic SCT, we hypothesized that a direct graft-versustumor (GVT) reaction could be induced in patients who had not had a prior allogeneic transplant. In our initial study, we treated 18 patients with a variety of malignancies with DLI as primary therapy without conditioning. 25 Sustained mixed chimerism at a level between 1 and 5% was achieved in four patients, and three patients had an antitumor response (two had Hodgkin's disease, and one had myeloma). Mixed chimerism and/or a GVT response occurred in only four of the 18 patients who had relapsed disease after a prior autologous transplant. Therefore, our data showed that donor cells could survive and induce a direct GVT reaction after primary DLI, but only in the most heavily pretreated patients. We therefore reasoned, as did others, [26] [27] [28] that preinfusion immunosuppressive therapy would enhance engraftment and hence the likelihood of an antitumor response. In addition, one of 18 patients developed severe aplasia. In order to minimize the risk of aplasia and enhance full donor chimerism, subsequent trials have infused G-CSF-stimulated allogeneic peripheral blood mononuclear cells after nonmyeloablative immunosuppressive conditioning.
Nonmyeloablative allogeneic (NMA) SCT has been tested in a variety of tumor types. Responses have been impressive for some patients with non-Hodgkin's lymphoma and Hodgkin's disease. 26, 28, 29 The role of NMA allogeneic SCT for patients with AML is less certain. Various regimens can induce a high rate of donor chimerism and even CR, but overall outcomes in several small trials have been poor, largely because of rapid relapse as well as other complications. 27, 30, 31 This is not surprising given the limited efficacy of GVL induction with DLI for patients with relapsed AML. Sustained remissions have been described primarily in patients receiving NMA-conditioned allogeneic SCT for AML while in remission. 28, [31] [32] [33] This is similar to reports of NST for ALL that suggest that this approach is most likely to be effective for patients with ALL transplanted in remission or with minimal leukemia cell burdens. 34 Follow-up is quite short in these trials, and it is difficult to distinguish the effects of the intensive (although nonmyeloablative) conditioning therapy from the possible GVL activity, but if these remissions remain durable, it suggests that GVL induction with this approach will be effective primarily for patients with minimal disease at the time of transplant. DLI therefore, clearly is effective for some patients with relapsed AML after both related and unrelated donor SCT. The remissions may be durable in many cases. Unfortunately, only a minority of patients enjoy long-term benefit, but the use of cytoreductive chemotherapy prior to DLI may improve response and outcome. Further investigation and development of new approaches for allogeneic cell therapy, both to maximize the GVL effects and minimize GVHD and toxicity, is underway.
